Urine and serum S100A8/A9 and S100A12 associate with active lupus nephritis and may predict response...
Urine and serum S100A8/A9 and S100A12 associate with active lupus nephritis and may predict response to rituximab treatment
About this item
Full title
Author / Creator
Publisher
England: EULAR
Journal title
Language
English
Formats
Publication information
Publisher
England: EULAR
Subjects
More information
Scope and Contents
Contents
BackgroundApproximately 30% of patients with the systemic autoimmune/inflammatory disorder systemic lupus erythematosus (SLE) develop lupus nephritis (LN) that affects treatment and prognosis. Easily accessible biomarkers do not exist to reliably predict renal disease. The Maximizing SLE Therapeutic Potential by Application of Novel and Systemic Ap...
Alternative Titles
Full title
Urine and serum S100A8/A9 and S100A12 associate with active lupus nephritis and may predict response to rituximab treatment
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_9b2576376c7440c59d9c09150dd9dcc5
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_9b2576376c7440c59d9c09150dd9dcc5
Other Identifiers
ISSN
2056-5933
E-ISSN
2056-5933
DOI
10.1136/rmdopen-2020-001257
